October 28, 2008
Morningstar health-care analysts offer their take on the candidates’ plans and their possible effects for health-care firms. Share this:
The third quarter saw some highly unusual activity on the part of FDA’s DDMAC in terms of both content and quantity. Addressing the latter first, the FDA issued 8 letters for the quarter, which is a substantial increase for the … Continue reading →
Here is a significant movement by FDA and a press release just received: The U.S. Food and Drug Administration today sent Warning Letters to Bayer HealthCare concerning two unlawful, over-the-counter (OTC) aspirin products — Bayer Women’s Low Dose Aspirin + … Continue reading →